Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN84,3584,380,39
Msft1,58
Nokia4,3894,48-0,27
IBM1,50
Mercedes-Benz Group AG50,1950,21-1,01
PFE0,24
04.07.2025 18:00:42
Indexy online
AD Index online
select
AD Index online
 

  • 04.07.2025 17:30:21
RELIEF THER Hlg Rg (Swiss Exchange)
Závěr k 4.7.2025 Změna (%) Změna (CHF) Objem obchodů (CHF)
2,15 0,94 0,02 51 771
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 06.07.2025
Popis společnosti
Obecné informace
Název společnostiRELIEF THERAPEUTICS Holding SA
TickerRLF
Kmenové akcie:Ordinary Shares
Kmenové akcie:Rights
RICRLFB.S
ISINCH1251125998
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 31
Akcie v oběhu k 03.06.2025 12 575 919
MěnaCHF
Kontaktní informace
UliceAvenue de Secheron 15
MěstoGENEVE
PSČ1202
ZeměSwitzerland
Kontatní osobaJeremy Meinen
Funkce kontaktní osobyChief Financial Officer
Telefon41 447 235 959
Fax41447269012

Business Summary: RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, RELIEF THERAPEUTICS Holding SA revenues increased 40% to SF8.4M. Net loss decreased 83% to SF17.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Impairment expense decrease of 82% to SF17.1M (expense), Personnel expenses - Balancing value decrease of 48% to SF5.7M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 06.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardRaghuram Selvaraju4725.05.201625.05.2016
Chief Financial OfficerJeremy Meinen3603.06.2024
Chief Scientific OfficerGiorgio Reiner6008.05.202401.01.2023
Chief Business OfficerPaolo Galfetti6008.05.2024
Head of Legal and ComplianceVincenzo Gallo3801.01.2023